[Calculation of orbital fat volumes for determining treatment timing for thyroid- associated ophthalmopathy].

OBJECTIVE To analyze the relationship between orbital fat volume and the progression and prognosis of thyroid- associated ophthalmopathy (TAO) and determine the optimal treatment timing for TAO. METHODS The clinical data were collected from 35 patients (70 orbits) with a definite diagnosis of TAO between January, 2016 and December, 2016. The correlation between orbital fat volume and the clinical parameters was evaluated. We also analyzed the correlation of the signal intensity ratio (SIR) of the extraocular muscles with the clinical parameters. The orbital fat volume was compared between patients with TAO and 12 control subjects. RESULTS The orbital fat volume was significantly correlated with the duration of TAO (r=0.480, P<0.01), but showed no significant difference between patients with a disease course within 6 months and those with a disease course of 6 to 12 months (P=0.084). The patients with a disease course beyond 12 months had a significantly greater orbital fat volume than those with a disease course of 6 months (P<0.01) or 6 to 12 months (P<0.05). The orbital fat volume was correlated with the degree of proptosis (r=0.622, P<0.01), and an increase of exophthalmos by 1 mm was associated with a total orbital volume increment of 0.88 mL. The clinical activity score was correlated with the SIR of the extraorbital muscles (r=0.536, P<0.01) and levels of anti-thyroid-stimulating hormone receptor antibody (r=0.416,P<0.01). The orbital fat volume was significantly greater in TAO patients than in the healthy individuals (P<0.01). CONCLUSION In patients with TAO, the peak increase of orbital fat volume occurs one year after the disease onset. Measurement of the orbital fat volume combined with SIR of the extraorbital muscles can serve as an indicator for determining the optimal timing for intervention of TAO and helps in the evaluation of prognosis of the patients.

[1]  W. Wiersinga,et al.  The 2016 European Thyroid Association/European Group on Graves' Orbitopathy Guidelines for the Management of Graves' Orbitopathy , 2016, European Thyroid Journal.

[2]  W. Dik,et al.  Current perspectives on the role of orbital fibroblasts in the pathogenesis of Graves' ophthalmopathy. , 2016, Experimental eye research.

[3]  J. Craig,et al.  Pathogenesis of thyroid eye disease: review and update on molecular mechanisms , 2015, British Journal of Ophthalmology.

[4]  Ji Min Kim,et al.  Volume Measurement of Various Tissues Using the Image J Software. , 2015, The Journal of craniofacial surgery.

[5]  Y. Nishida,et al.  Changes of orbital tissue volumes and proptosis in patients with thyroid extraocular muscle swelling after methylprednisolone pulse therapy , 2015, Japanese Journal of Ophthalmology.

[6]  W. Wiersinga,et al.  Some studies on the natural history of Graves' orbitopathy: increase in orbital fat is a rather late phenomenon. , 2015, European journal of endocrinology.

[7]  H. Lew,et al.  Usefulness of the ratio of orbital fat to total orbit area in mild-to-moderate thyroid-associated ophthalmopathy. , 2015, The British journal of radiology.

[8]  B. Llamas,et al.  Differential Gene Expression Profiling of Orbital Adipose Tissue in Thyroid Orbitopathy. , 2015, Investigative ophthalmology & visual science.

[9]  Wenting Li,et al.  Th1, Th2, and Th17 Cytokine Involvement in Thyroid Associated Ophthalmopathy , 2015, Disease markers.

[10]  W. Wiersinga,et al.  Differential Involvement of Orbital Fat and Extraocular Muscles in Graves' Ophthalmopathy , 2013, European Thyroid Journal.

[11]  A. Majos,et al.  Signal intensity and T2 time of extraocular muscles in assessment of their physiological status in MR imaging in healthy subjects , 2012, Polish journal of radiology.

[12]  A. Leontovich,et al.  Gene expression profiling of orbital adipose tissue from patients with Graves' ophthalmopathy: a potential role for secreted frizzled-related protein-1 in orbital adipogenesis. , 2005, The Journal of clinical endocrinology and metabolism.

[13]  L. Galuska,et al.  Volume changes in intra- and extraorbital compartments in patients with Graves' ophthalmopathy: effect of smoking. , 2005, Thyroid : official journal of the American Thyroid Association.

[14]  P. Scherer,et al.  Evidence for enhanced adipogenesis in the orbits of patients with Graves' ophthalmopathy. , 2004, The Journal of clinical endocrinology and metabolism.

[15]  M. Ludgate,et al.  Adipose thyrotrophin receptor expression is elevated in Graves' and thyroid eye diseases ex vivo and indicates adipogenesis in progress in vivo. , 2003, Journal of molecular endocrinology.

[16]  G. Lennerstrand,et al.  Significance of orbital fatty tissue for exophthalmos in thyroid-associated ophthalmopathy , 2002, Graefe's Archive for Clinical and Experimental Ophthalmology.

[17]  Terry J. Smith,et al.  Orbital fibroblast heterogeneity may determine the clinical presentation of thyroid-associated ophthalmopathy. , 2002, The Journal of clinical endocrinology and metabolism.

[18]  T. Bednarczuk,et al.  Cytokine profiles in eye muscle tissue and orbital fat tissue from patients with thyroid-associated ophthalmopathy. , 2000, The Journal of clinical endocrinology and metabolism.

[19]  R. Bahn,et al.  Relationship between disease duration and predominant orbital T cell subset in Graves' ophthalmopathy. , 2000, The Journal of clinical endocrinology and metabolism.

[20]  N. Hosten,et al.  Graves ophthalmopathy: MR imaging of the orbits. , 1989, Radiology.

[21]  J. Silber,et al.  Exophthalmos caused by excessive fat: CT volumetric analysis and differential diagnosis. , 1986, AJR. American journal of roentgenology.